Bizarre Patents
Smoking Cessation Lighter and Method
A lighter for tobacco products suppresses the urge to smoke by operant conditioning.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110123537 | BINDING EPITOPES FOR G250 ANTIBODY The invention relates to specific amino acid sequences which have been determined to be target epitope for antibodies, in particular, for a G250 antibody.... | 05/26/2011 |
| 20100068272 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urok... | 03/18/2010 |
| 20100008888 | CO-ADMINISTRATION OF CG250 AND IL-2 OR IFN-ALPHA FOR TREATING CANCER SUCH AS RENAL CELL CARCINOMAS A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor as... | 01/14/2010 |
| 20090274620 | Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives ... | 11/05/2009 |
| 20090202550 | MONOCLONAL ANTIBODIES AND IMMUNODETECTION ASSAY SPECIFIC FOR THE CHEMOTACTIC EPITOPE OF THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR The present invention describes monoclonal antibodies specific for the chemotactic epitope of the uPAR. In particular, the invention comprises monoclonal antibodies against uPAR fragments specifically recognizing in whole or in part the chemotactic sequence of uPAR conn... | 08/13/2009 |
| 20090202504 | METHODS FOR THE DETECTION AND PROGNOSIS OF BREAST TUMORS This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.... | 08/13/2009 |
| 20080261998 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urok... | 10/23/2008 |
| 20080138275 | Hybridoma cell line G250 and its use for producing monoclonal antibodies This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well a... | 06/12/2008 |
| 20060189689 | Arginine mimetics as factor Xa inhibitors The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor Xa; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic thera... | 08/24/2006 |
| 20060142305 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urok... | 06/29/2006 |
| 20060105943 | Cyclic peptidomimetic urokinase receptor antagonists The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor. ... | 05/18/2006 |
| 20050101526 | Cyclic peptidomimetic urokinase receptor antagonists The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor. ... | 05/12/2005 |
